'If you could have the next Prozac, that’s intoxicating': Sage’s postpartum depression triumph and the failure that followed

Ryan Cross

Senior Science Correspondent

In 2015, psychiatrist Samantha Meltzer-Brody saw an unbelievable transformation in a new mother who had been admitted to her psychiatry clinic. Withdrawn and having suicidal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'If you could have the next Prozac, that’s intoxicating': Sage’s postpartum depression triumph and the failure that followed

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

'If you could have the next Prozac, that’s in­tox­i­cat­ing': Sage’s post­par­tum de­pres­sion tri­umph and the fail­ure that fol­lowed

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

'If you could have the next Prozac, that’s intoxicating': Sage’s postpartum depression triumph and the failure that followed

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A